💼 My Portfolio 👁 Watchlist 🧠 AI Stock Analysis 🤖 AI Portfolio Analysis 📊 Fear & Greed 💬 Community 🔴 Live 📰 Archives 🛒 Shop

← Back to Screener

OPKO Health

OPK Small Cap

Healthcare · Diagnostics & Research

Updated: May 22, 2026, 22:06 UTC

$1.27
-0.78% today
52W: $0.98 – $1.60
52W Low: $0.98 Position: 46.8% 52W High: $1.60

Key Metrics

P/E Ratio
—
Price-to-Earnings
Forward P/E
—
Forward Price/Earnings
P/S Ratio
1.65x
Price-to-Sales
EV/EBITDA
—
Enterprise Value/EBITDA
Div. Yield
—
Annual dividend yield
Market Cap
$959M
Market Capitalization
Revenue Growth
-17.2%
YoY Revenue Growth
Profit Margin
-36.64%
Net profit margin
ROE
-16.92%
Return on Equity
Beta
1.41
Market sensitivity
Short Interest
7.97%
% of float sold short
Avg. Volume
2,447,976
Average daily volume

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Buy
5 analysts
Avg. Price Target
$3.76
+196.06% upside
Target Range
$1.30 – $8.50

About the Company

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose a

Sector: Healthcare Industry: Diagnostics & Research Country: United States Employees: 2,275 Exchange: NMS

OPKO Health Stock at a Glance

OPKO Health (OPK) is currently trading at $1.27 with a market capitalization of $959M. The 52-week range spans from $0.98 to $1.60; the current price is 20.6% below the yearly high. Year-over-year revenue growth stands at -17.2%.

💰 Dividend

OPKO Health currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

5 analysts rate OPKO Health (OPK) on consensus: Buy. The average price target is $3.76, implying +196.06% from the current price. Analyst price targets range from $1.30 to $8.50.

Investment Thesis: Strengths & Weaknesses

Strengths
  • Analyst consensus: Buy
  • Solid balance sheet with low debt (D/E 32.95)
Weaknesses
  • –Revenue shrinking (-17.2% YoY)
  • –Currently unprofitable
  • –Negative free cash flow

Technical Snapshot

50-Day MA
$1.16
+9.48% vs. price
200-Day MA
$1.30
-2.31% vs. price
Below 52W High
−20.6%
$1.60
Above 52W Low
+29.6%
$0.98

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

Market Risk (Beta)
1.41 · Elevated
Moves more than the overall market
Short Interest
7.97% · Elevated
% of float sold short
Debt-to-Equity
32.95 · Low
Total debt / equity

The data points to market-like volatility, elevated short interest (7.97%).

Trading Data

50-Day MA: $1.16
200-Day MA: $1.30
Volume: 3,127,485
Avg. Volume: 2,447,976
Short Ratio: 14.51
P/B Ratio: 0.76x
Debt/Equity: 32.95x
Free Cash Flow: $-36,094,624

OPKO Health (OPK) 2026: 1,10 USD US Pharmaceutical-and-Diagnostics Holding with Phillip Frost Founder Anchor, BioReference Laboratories Divestiture, Rayaldee Renal-Bone Franchise and Pfizer Somatrogon Royalty

The Real Story

OPKO Health Inc. (NASDAQ: OPK) is a Miami, Florida-headquartered diversified-healthcare company founded by Phillip Frost (former Teva-Pharmaceutical-Industries chairman and serial-biotech-investor). Two segments: Pharmaceutical (Rayaldee renal-bone-mineral, RAYALDEE oral-calcifediol for secondary-hyperparathyroidism in CKD-stage-3-and-4; Modeling-Insights and Eaton drug-discovery-platforms; ModeRNA-platform partnerships) and Diagnostics (BioReference Laboratories clinical-lab-services, in restructuring-and-divestiture process). Pfizer-licensed somatrogon (Ngenla long-acting growth-hormone) royalty stream.

Strategic-pivot: BioReference Laboratories sale-process announced 2024 with multiple-bidder engagement; pharmaceutical-segment-focus on Rayaldee and pipeline-development.

What Smart Money Thinks

OPKO Health has founder-aligned base. Phillip Frost via Frost Gamma Investments holds approximately 30+ percent — dominant founder-anchor since founding. Vanguard at approximately 5,8 percent, BlackRock at approximately 4,2 percent represent passive flows. Frost is structurally-aligned with long-duration value-realization. Short-interest sits at approximately 8 percent of float as of May 2026.

Explore the BMI Smart-Money Tracker →

📈 The 3 Real Bull Points

#1 BioReference Laboratories divestiture sale process creates value-realization catalyst — potential 300-600 million USD proceeds

BioReference Laboratories sale-process with multiple-bidder engagement (Quest Diagnostics, Labcorp, Roper Technologies named as potential buyers per industry press) could generate 300-600 million USD proceeds for OPKO. Net cash proceeds equate to approximately 0,40-0,80 USD per share — substantial relative to current 1,10 USD share-price.

#2 Pfizer Ngenla (somatrogon long-acting growth hormone) royalty stream provides recurring revenue base

OPKO receives royalty stream from Pfizer Ngenla (somatrogon) which has been FDA-approved-and-EU-approved long-acting growth-hormone for pediatric-growth-hormone-deficiency. Royalty-stream supports approximately 30-50 million USD annual recurring revenue and growing as Ngenla launches scale.

#3 Phillip Frost founder-anchor at 30+ percent provides long-duration capital-allocation discipline

Phillip Frost's 30+ percent ownership through Frost Gamma plus 30-year serial-biotech-investor track-record (founder of Teva, multiple-other-biotech-successes) provides structural capital-allocation discipline. Frost is structurally-aligned with long-duration value-realization.

📉 The 3 Real Bear Points

#1 Pre-profit operating burn requires capital-raise risk — dilution overhang at low share-price

OPKO continues to operate near-cash-flow break-even with periodic capital-raise requirements. At 1,10 USD share-price, additional equity-issuance creates significant dilution risk.

#2 Rayaldee commercial-execution disappointment plus competitive pressure compresses pharma-segment value

Rayaldee oral-calcifediol commercial-launch has historically underperformed initial expectations. Continued under-performance plus competitive pressure from cinacalcet-and-other-treatments could compress pharma-segment value.

#3 BioReference Laboratories sale-execution risk — pricing-and-timing uncertain

BioReference Laboratories sale-process pricing-and-timing remains uncertain. Lower-than-expected sale price or delayed-execution could compress value-realization channel.

Valuation in Context

OPKO at 1,10 USD per share with approximately 755 million shares outstanding has a market capitalization of approximately 831 million USD. With minimal net-cash, enterprise value approximately equal to market-cap. TTM revenue approximately 700 million USD (primarily BioReference Laboratories).

Sum-of-parts: BioReference Laboratories sale 0,40-0,80 USD per share; Pharmaceutical segment (Rayaldee plus pipeline plus royalty) 0,30-0,70 USD per share; cash and other 0,20-0,40 USD per share. Fair-value range 0,90-1,90 USD per share. Bear-case 0,60-0,80 USD. Bull-case (BioReference sale at premium plus pipeline progression) 2,20-2,80 USD over 18-24 months.

🗓️ Next 3 Catalyst Dates

  1. 2026 Q3:

    Q2 2026 earnings (early August 2026). Watch-items: BioReference Laboratories sale-process update, Rayaldee commercial trajectory, Ngenla royalty stream.

  2. 2026 H2:

    BioReference Laboratories sale-process resolution (expected H2 2026 per management commentary).

  3. 2027 Q1:

    Fiscal-2026 full-year results plus fiscal-2027 guidance. BioReference sale plus pharma-segment focus would unlock 1,80-2,40 USD range.

💬 Daniel's Take

OPKO Health is a deep-value sum-of-parts US pharma-and-diagnostics holding with Phillip Frost founder-anchor, BioReference Laboratories divestiture catalyst, Pfizer Ngenla royalty stream, and Rayaldee renal-bone-mineral franchise. Position-sizing: 0,3–0,8 percent in deep-value-event-driven sleeve.

Sources (3)

Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.

Where can I buy OPKO Health?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Scroll to Top
WordPress Cookie Notice by Real Cookie Banner